WBI Investments LLC Acquires New Holdings in Becton, Dickinson and Company $BDX

Key Points

• WBI Investments LLC acquired a new stake in Becton, Dickinson and Company during the first quarter, purchasing 3,806 shares valued at approximately $872,000.
• Becton, Dickinson and Company reported earnings of $3.68 per share for the last quarter, exceeding analysts' expectations of $3.40, with revenues up 10.4% year-over-year.
• The company's dividend will be $1.04 per share, yielding 2.2%, payable on September 30th to investors of record on September 8th.

WBI Investments LLC acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 3,806 shares of the medical instruments supplier's stock, valued at approximately $872,000.

Other institutional investors have also added to or reduced their stakes in the company. Saudi Central Bank acquired a new stake in Becton, Dickinson and Company in the first quarter worth about $26,000. Smallwood Wealth Investment Management LLC purchased a new position in shares of Becton, Dickinson and Company in the first quarter worth about $27,000. Alpine Bank Wealth Management purchased a new position in Becton, Dickinson and Company during the first quarter valued at approximately $29,000. REAP Financial Group LLC raised its position in Becton, Dickinson and Company by 75.3% during the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 55 shares in the last quarter. Finally, Cornerstone Planning Group LLC increased its position in shares of Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after buying an additional 99 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Claire Fraser sold 863 shares of the stock in a transaction on Friday, August 8th. The shares were sold at an average price of $192.30, for a total value of $165,954.90. Following the sale, the director owned 23,143 shares in the company, valued at approximately $4,450,398.90. This trade represents a 3.59% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Stock Down 1.0%

Becton, Dickinson and Company stock opened at $188.57 on Thursday. The stock has a market capitalization of $54.05 billion, a price-to-earnings ratio of 33.91, a PEG ratio of 1.42 and a beta of 0.27. The stock has a 50 day moving average of $185.95 and a two-hundred day moving average of $192.31. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. The business had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company's revenue for the quarter was up 10.4% on a year-over-year basis. During the same period in the prior year, the business posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, research analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be paid a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 74.82%.

Analysts Set New Price Targets

BDX has been the subject of a number of recent analyst reports. Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Morgan Stanley boosted their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Citigroup lowered Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and decreased their price target for the company from $217.00 to $185.00 in a research note on Thursday, May 22nd. Piper Sandler reiterated a "neutral" rating and issued a $200.00 price objective (up previously from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Wells Fargo & Company boosted their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a report on Friday, August 8th. Four research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $211.44.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.